The Conversation (0)
Asterias Biotherapeutics announced the publication of a peer-reviewed journal describing the efficacy and safety data from a preclinical study on AST-OPC1 as they were submitted for approval to the US Food and Drug Administration.
Asterias Biotherapeutics (NYSE:AST) announced the publication of a peer-reviewed journal describing the efficacy and safety data from a preclinical study on AST-OPC1 as they were submitted for approval to the US Food and Drug Administration (FDA).
As quoted in the press release:
AST-OPC1 is currently being investigated in the company’s ongoing SCiStar Phase 1/2a clinical trial in patients with severe cervical spinal cord injury (SCI).
The preclinical results showed that AST-OPC1 cells improved locomotor performance after cervical spinal cord injury and that this functional improvement was associated with reduced parenchymal cavitation and increased sparing of myelinated axons within the injury site. In addition, AST-OPC1 cells exhibited limited migration within the cervical spinal cord and did not cause any adverse clinical observations, toxicities, allodynia or tumors.
Click here to read the full press release.
Source: globenewswire.com